Natera Inc (NASDAQ:NTRA) CFO Michael Burkes Brophy sold 108,108 shares of the business’s stock in a transaction dated Friday, September 14th. The stock was sold at an average price of $24.31, for a total transaction of $2,628,105.48. Following the sale, the chief financial officer now owns 22,000 shares in the company, valued at $534,820. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.
Michael Burkes Brophy also recently made the following trade(s):
- On Monday, September 24th, Michael Burkes Brophy sold 446 shares of Natera stock. The stock was sold at an average price of $23.78, for a total transaction of $10,605.88.
- On Monday, July 2nd, Michael Burkes Brophy sold 26,870 shares of Natera stock. The stock was sold at an average price of $18.29, for a total transaction of $491,452.30.
- On Friday, June 22nd, Michael Burkes Brophy sold 266 shares of Natera stock. The stock was sold at an average price of $13.95, for a total transaction of $3,710.70.
Shares of NTRA stock traded up $0.66 during mid-day trading on Friday, reaching $20.77. The stock had a trading volume of 461,912 shares, compared to its average volume of 422,908. The stock has a market cap of $1.46 billion, a P/E ratio of -8.65 and a beta of 2.24. Natera Inc has a 12-month low of $8.60 and a 12-month high of $29.62. The company has a quick ratio of 1.56, a current ratio of 1.69 and a debt-to-equity ratio of -3.32.
A number of equities analysts recently issued reports on NTRA shares. JPMorgan Chase & Co. started coverage on Natera in a report on Friday, October 5th. They issued a “neutral” rating and a $26.00 price objective for the company. Morgan Stanley increased their price objective on Natera from $21.00 to $41.00 and gave the company an “overweight” rating in a report on Friday, September 28th. Canaccord Genuity increased their price target on Natera from $25.00 to $29.00 and gave the stock a “buy” rating in a report on Thursday, August 16th. Zacks Investment Research raised Natera from a “sell” rating to a “hold” rating in a report on Thursday, June 21st. Finally, Robert W. Baird increased their price target on Natera from $17.00 to $20.00 and gave the stock an “outperform” rating in a report on Thursday, June 28th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average target price of $26.00.
A number of large investors have recently modified their holdings of the business. Bank of New York Mellon Corp boosted its stake in Natera by 9.8% in the 2nd quarter. Bank of New York Mellon Corp now owns 650,968 shares of the medical research company’s stock worth $12,251,000 after buying an additional 58,224 shares during the last quarter. Jane Street Group LLC acquired a new position in shares of Natera in the 2nd quarter valued at about $313,000. Millennium Management LLC lifted its stake in shares of Natera by 135.5% in the 2nd quarter. Millennium Management LLC now owns 744,598 shares of the medical research company’s stock valued at $14,013,000 after purchasing an additional 428,376 shares in the last quarter. Macquarie Group Ltd. lifted its stake in shares of Natera by 9.0% in the 2nd quarter. Macquarie Group Ltd. now owns 1,714,886 shares of the medical research company’s stock valued at $32,274,000 after purchasing an additional 141,278 shares in the last quarter. Finally, Cubist Systematic Strategies LLC acquired a new position in shares of Natera in the 2nd quarter valued at about $252,000. 66.31% of the stock is currently owned by hedge funds and other institutional investors.
Natera, Inc, a diagnostics company, provides preconception and prenatal genetic testing services. It primarily offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases that could be passed on to the carrier's children; and Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.
Featured Story: Asset Allocation Models, Which is Right For You?
Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.